Author Archives: Marisa Wexler MS

A new research project aiming to better understand how fat cells help multiple myeloma cells resist treatment has won a $1.9 million grant from the National Cancer Institute of the National Institutes of Health. The five-year funding was awarded to Michaela Reagan, PhD, a faculty scientist at…

A combination of Sarclisa (isatuximab) plus standard Kyprolis (carfilzomib) and dexamethasone treatment significantly delays disease progression or death in people with relapsed or refractory multiple myeloma, interim results from a Phase 3 clinical trial suggest. The findings were shared at the European Hematology Association (EHA) 2020 Virtual Congress,…

A computer program developed by GNS Healthcare could be used to model and predict disease progression and response to treatment in people with multiple myeloma. Called “Gemini, the in silico ” Patient” (“in silico” refers to analyses done using computer simulation), the program was built through a…

The U.K.’s National Institute for Health and Care Excellence (NICE) has issued a draft “no” statement on the triple combination of Sarclisa (isatuximab), Pomalyst (pomalidomide) and dexamethasone as a treatment for people with relapsed or refractory multiple myeloma. This draft decision means that, at present, NICE will not…

The European Commission (EC) has approved Sanofi‘s Sarclisa (isatuximab), in a triple combination with Pomalyst (pomalidomide) and dexamethasone, to treat adults with relapsed or refractory multiple myeloma. The approval is specifically for those who have tried at least two previous types of treatment, to include…

A new technology that measures the levels of proteins in individual cells could help to identify therapy combinations that might more effectively treat people with multiple myeloma, a study suggests. Its researchers also report that lowering levels of a particular protein on myeloma cells, MCL-1, may make them more responsive…

A novel genetic test could help identify people with multiple myeloma who are at highest risk of aggressive disease and unlikely to respond to standard treatment with Revlimid (lenalidomide), a new study shows. The study, “Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis…

Preventive treatment with the antibiotic levofloxacin can lower the incidence of fever and death in people newly diagnosed with multiple myeloma, results from a Phase 3 clinical trial suggest. The optimal length of time for treatment remains to be determined. Results from the trial were published in The…

Sanofi announced that it partnered with Sebia to develop a new multiple myeloma diagnostic test that will help to mitigate the interference of isatuximab when measuring levels of monoclonal protein — a marker of disease severity — in a person’s blood. Myeloma is a cancer of plasma cells, the…

For people with multiple myeloma who don’t respond well to an initial type of therapy, quickly switching to another type may improve clinical outcomes, a new study suggests. The study, “Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple…